MedElevator
Войти в исследования Journal of ethnopharmacology · 2025
Metabolomic profiling of Piper sarmentosum Roxb. Extracts reveals potent xanthine oxidase inhibition and anti-inflammatory effects.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tai Do Chiem, Le Hang Dang Thi, Minh Nhut Kieu Dang, Anh Thu Do Nguyen, Cuong Tran Hoai, Xuan Phuong Nguyen Tran, Thuy Trang Nguyen Thi, Nhat Trinh Pham Thi, Dung Le Tien
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Piper sarmentosum (Psar) is widely used in traditional medicine across Vietnam, Thailand, and Malaysia to treat joint pain, inflammation, and digestive ailments. In Vietnam, Psar is commonly used to relieve symptoms associated with gout. Despite its broad ethnomedical applications, the plant has not been comprehensively studied for its anti-gout properties, particularly xanthine oxidase (XO) inhibition.
AIM OF THE STUDY: This study aimed to scientifically validate the traditional use of Piper sarmentosum for gout management by evaluating its antioxidant, anti-inflammatory, and XO inhibitory activities. It further aimed to identify key bioactive compounds through LC/MS-based metabolomic profiling and bioassay-guided isolation.
METHODS: Psar aerial part were extracted using solvents of varying polarity (50 % ethanol, 96 % ethanol, hexane, ethyl acetate, methanol), and fractionated. Antioxidant capacity was evaluated via DPPH, ABTS, FRAP, H2O2, and NO scavenging assays. Anti-inflammatory activity was assessed in vitro using LPS-induced RAW264.7 macrophages (NO, TNF-α, IL-6 assays) and in vivo using a carrageenan-induced paw edema mouse model. XO inhibition was determined via spectrophotometric assays. LC/MS-GNPS molecular networking was employed for metabolomic profiling, and seven bioactive compounds were isolated and characterized using NMR spectroscopy.
RESULTS: The ethyl acetate fraction (PLEA) exhibited the strongest XO inhibition (IC50 value of 13.90 ± 0.82 μg/mL) and antioxidant activity. PLE50 and PLE96 significantly reduced carrageenan-induced paw edema in mice. Among the seven isolated compounds, chrysin displayed outstanding XO inhibition (IC50 value of 2.05 ± 0.04 μM), outperforming allopurinol (IC50 = 4.80 ± 0.11 μM), along with notable NO and TNF-α inhibition. LC/MS-GNPS revealed differential metabolite profiles in PLE50 and PLE96 extracts, highlighting the influence of solvent polarity on pharmacological activity.
CONCLUSION: This is the first study to validate the traditional use of Piper sarmentosum for gout using modern metabolomic and pharmacological approaches. The results support its ethnopharmacological role as a natural XO inhibitor and anti-inflammatory agent. Chrysin, in particular, emerges as a promising lead compound. Further studies using monosodium urate-induced gout models and clinical validation are warranted.
AIM OF THE STUDY: This study aimed to scientifically validate the traditional use of Piper sarmentosum for gout management by evaluating its antioxidant, anti-inflammatory, and XO inhibitory activities. It further aimed to identify key bioactive compounds through LC/MS-based metabolomic profiling and bioassay-guided isolation.
METHODS: Psar aerial part were extracted using solvents of varying polarity (50 % ethanol, 96 % ethanol, hexane, ethyl acetate, methanol), and fractionated. Antioxidant capacity was evaluated via DPPH, ABTS, FRAP, H2O2, and NO scavenging assays. Anti-inflammatory activity was assessed in vitro using LPS-induced RAW264.7 macrophages (NO, TNF-α, IL-6 assays) and in vivo using a carrageenan-induced paw edema mouse model. XO inhibition was determined via spectrophotometric assays. LC/MS-GNPS molecular networking was employed for metabolomic profiling, and seven bioactive compounds were isolated and characterized using NMR spectroscopy.
RESULTS: The ethyl acetate fraction (PLEA) exhibited the strongest XO inhibition (IC50 value of 13.90 ± 0.82 μg/mL) and antioxidant activity. PLE50 and PLE96 significantly reduced carrageenan-induced paw edema in mice. Among the seven isolated compounds, chrysin displayed outstanding XO inhibition (IC50 value of 2.05 ± 0.04 μM), outperforming allopurinol (IC50 = 4.80 ± 0.11 μM), along with notable NO and TNF-α inhibition. LC/MS-GNPS revealed differential metabolite profiles in PLE50 and PLE96 extracts, highlighting the influence of solvent polarity on pharmacological activity.
CONCLUSION: This is the first study to validate the traditional use of Piper sarmentosum for gout using modern metabolomic and pharmacological approaches. The results support its ethnopharmacological role as a natural XO inhibitor and anti-inflammatory agent. Chrysin, in particular, emerges as a promising lead compound. Further studies using monosodium urate-induced gout models and clinical validation are warranted.